1479PFirst analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

Background: In September 2016, the SLCG began a RTT in 53 Spanish hospitals. In this study, we present data on patients with NSCLC with advanced disease. Methods: The study comprises all the patients included in the RTT since September 2016 with stage IV disease. Progressionfree survival (PFS) and overall survival (OS) were evaluated with the Kaplan-Meier curves and the groups were compared using the Log-rank test. The variables related with the patients that were analyzed included: age, gender, smoking habit, comorbidities, performance status (PS) by ECOG and histology of the tumor. The molecular tests performed in the group of patients with advanced disease were also analyzed. We also analyzed the treatment received in this patient cohort. Results: Out of the total of 2361 patients included, diagnosed between July 1991 and April 2018, 1194 had stage IV NSCLC. Mean age was 63.2 years, 824 (69%) were males, 473 (39.6%) active smokers and 475 (39.8%) ex-smokers. The most frequent histology was adenocarcinoma, in 894 patients (74.9%), and squamous cell, in 220 patients (18.4%). A total of 78.6% (938) of the patients had some type of comorbidity: HBP (38.5%), dyslipidemia (28.1%), diabetes mellitus (16.3%) and COPD (14.7%). A total of 978 patients (81.9%) underwent some type of molecular test. The EGFR analysis was performed in 900 patients (75.4%), and was positive in 25.6%. ALP was analyzed in 763 patients (63.9%), mostly by IHC (44.7%), 5.2% being positive by this method. Of the total, 158 patients (13.2%) did not receive any treatment, 530 patients (44.4%) received 1 treatment line, 295 patients (24.7%) two lines, 128 patients (10.7%) three lines, and 30 patients (2.5%) 4 or more lines. A total of 60.9% of the patients received a platinum doublet in first line, the most commonly used being the combination of platinum with pemetrexed (34%). 1171 patients are evaluable for overall survival, with a median survival of 17.4 m (95% CI 14.6-20.2 m). Conclusions: In this cohort of patients, the clinical characteristics are those expected for this group of patients with advanced disease. However, a greater percentage than that expected of the EGFR mutations appears, perhaps due to a population supraselection. Legal entity responsible for the study: Spanish Lung Cancer Group / Grupo Español de Cáncer de Pulmón (SLCG/GECP). Funding: Lilly, Msd, Novartis. Disclosure: All authors have declared no conflicts of interest.